507 related articles for article (PubMed ID: 14982654)
21. [Screening of newborns for inborn errors of metabolism by tandem mass spectrometry].
Simonsen H
Ugeskr Laeger; 2002 Nov; 164(48):5607-12. PubMed ID: 12523003
[TBL] [Abstract][Full Text] [Related]
22. Diagnosis and therapeutic monitoring of inborn errors of metabolism in 100,077 newborns from Jining city in China.
Yang CJ; Wei N; Li M; Xie K; Li JQ; Huang CG; Xiao YS; Liu WH; Chen XG
BMC Pediatr; 2018 Mar; 18(1):110. PubMed ID: 29534692
[TBL] [Abstract][Full Text] [Related]
23. Newborn screening for all identifiable disorders with tandem mass spectrometry is cost effective: supporting arguments.
Therrell BL; Buechner C
Ann Acad Med Singap; 2008 Dec; 37(12 Suppl):32-4. PubMed ID: 19904443
[TBL] [Abstract][Full Text] [Related]
24. Newborn screening by tandem mass spectrometry for glutaric aciduria type 1: a cost-effectiveness analysis.
Pfeil J; Listl S; Hoffmann GF; Kölker S; Lindner M; Burgard P
Orphanet J Rare Dis; 2013 Oct; 8():167. PubMed ID: 24135440
[TBL] [Abstract][Full Text] [Related]
25. Incidence and genetic variants of inborn errors of metabolism identified through newborn screening: A 7-year study in eastern coastal areas of China.
Men S; Liu S; Zheng Q; Yang S; Mao H; Wang Z; Gu Y; Tang X; Wang L
Mol Genet Genomic Med; 2023 Jun; 11(6):e2152. PubMed ID: 36787440
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and outcome of expanded newborn screening for metabolic diseases--report of 10 years from South-West Germany.
Lindner M; Gramer G; Haege G; Fang-Hoffmann J; Schwab KO; Tacke U; Trefz FK; Mengel E; Wendel U; Leichsenring M; Burgard P; Hoffmann GF
Orphanet J Rare Dis; 2011 Jun; 6():44. PubMed ID: 21689452
[TBL] [Abstract][Full Text] [Related]
27. Expanded newborn screening for inborn errors of metabolism by electrospray ionization-tandem mass spectrometry: results, outcome, and implications.
Schulze A; Lindner M; Kohlmüller D; Olgemöller K; Mayatepek E; Hoffmann GF
Pediatrics; 2003 Jun; 111(6 Pt 1):1399-406. PubMed ID: 12777559
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness analysis of newborn screening by tandem mass spectrometry in Shenzhen, China: value and affordability of new screening technology.
Yu M; Xu J; Song X; Du J
BMC Health Serv Res; 2022 Aug; 22(1):1039. PubMed ID: 35971172
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of electrospray-tandem mass spectrometry for the detection of phenylketonuria and other rare disorders.
Lukacs Z; Santer R
Mol Nutr Food Res; 2006 Apr; 50(4-5):443-50. PubMed ID: 16598811
[TBL] [Abstract][Full Text] [Related]
30. Health economic analysis of the neonatal screening program in Japan.
Hisashige A
Int J Technol Assess Health Care; 1994; 10(3):382-91. PubMed ID: 8071001
[TBL] [Abstract][Full Text] [Related]
31. Comprehensive cost-utility analysis of newborn screening strategies.
Carroll AE; Downs SM
Pediatrics; 2006 May; 117(5 Pt 2):S287-95. PubMed ID: 16735255
[TBL] [Abstract][Full Text] [Related]
32. Selective screening for inborn errors of metabolism by tandem mass spectrometry at Sohag University Hospital, Egypt.
Magdy RM; Abd-Elkhalek HS; Bakheet MA; Mohamed MM
Arch Pediatr; 2022 Jan; 29(1):36-43. PubMed ID: 34848132
[TBL] [Abstract][Full Text] [Related]
33. Cost effectiveness of establishing a neonatal screening programme for phenylketonuria in Libya.
Sladkevicius E; Pollitt RJ; Mgadmi A; Guest JF
Appl Health Econ Health Policy; 2010; 8(6):407-20. PubMed ID: 21043542
[TBL] [Abstract][Full Text] [Related]
34. Secondary analysis of economic data: a review of cost-benefit studies of neonatal screening for phenylketonuria.
Lord J; Thomason MJ; Littlejohns P; Chalmers RA; Bain MD; Addison GM; Wilcox AH; Seymour CA
J Epidemiol Community Health; 1999 Mar; 53(3):179-86. PubMed ID: 10396496
[TBL] [Abstract][Full Text] [Related]
35. Expanded newborn screening by tandem mass spectrometry: the Massachusetts and New England experience.
Marsden D
Southeast Asian J Trop Med Public Health; 2003; 34 Suppl 3():111-4. PubMed ID: 15906712
[TBL] [Abstract][Full Text] [Related]
36. [Tandem mass spectrometry as screening for inborn errors of metabolism].
Campos H D
Rev Med Chil; 2011 Oct; 139(10):1356-64. PubMed ID: 22286738
[TBL] [Abstract][Full Text] [Related]
37. Economic evaluation of tandem mass spectrometry newborn screening in Australia.
Norman R; Haas M; Chaplin M; Joy P; Wilcken B
Pediatrics; 2009 Feb; 123(2):451-7. PubMed ID: 19171609
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of neonatal screening for medium chain acyl-CoA dehydrogenase deficiency: the homogeneous population of The Netherlands.
van der Hilst CS; Derks TG; Reijngoud DJ; Smit GP; TenVergert EM
J Pediatr; 2007 Aug; 151(2):115-20, 120.e1-3. PubMed ID: 17643759
[TBL] [Abstract][Full Text] [Related]
39. Outcomes in pediatric studies of medium-chain acyl-coA dehydrogenase (MCAD) deficiency and phenylketonuria (PKU): a review.
Pugliese M; Tingley K; Chow A; Pallone N; Smith M; Rahman A; Chakraborty P; Geraghty MT; Irwin J; Tessier L; Nicholls SG; Offringa M; Butcher NJ; Iverson R; Clifford TJ; Stockler S; Hutton B; Paik K; Tao J; Skidmore B; Coyle D; Duddy K; Dyack S; Greenberg CR; Ghai SJ; Karp N; Korngut L; Kronick J; MacKenzie A; MacKenzie J; Maranda B; Mitchell JJ; Potter M; Prasad C; Schulze A; Sparkes R; Taljaard M; Trakadis Y; Walia J; Potter BK;
Orphanet J Rare Dis; 2020 Jan; 15(1):12. PubMed ID: 31937333
[TBL] [Abstract][Full Text] [Related]
40. Inborn errors of metabolism detectable by tandem mass spectrometry in Egypt: The first newborn screening pilot study.
Hassan FA; El-Mougy F; Sharaf SA; Mandour I; Morgan MF; Selim LA; Hassan SA; Salem F; Oraby A; Girgis MY; Mahmoud IG; El-Badawy A; El-Nekhely I; Moharam N; Mehaney DA; Elmonem MA
J Med Screen; 2016 Sep; 23(3):124-9. PubMed ID: 26790708
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
